Hims & Hers Health (82W) Stock Forecast & Price Target

Compare

32 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

82W Analyst Ratings

Hold

2 Buy

6 Hold

3 Sell

Based on 11 analysts giving stock ratings to

Hims

& Hers Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

82W Stock 12 Month Forecast

Average Price Target

€37.97

▲(28.37% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is €37.97 with a high forecast of €72.19 and a low forecast of €25.48. The average price target represents a 28.37% change from the last price of €29.58.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"€24","73":"€73","36.25":"€36.3","48.5":"€48.5","60.75":"€60.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72.1887983,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€72.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.9713079058,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€37.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.4783994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€25.48</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,36.25,48.5,60.75,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.16,36.16221525384615,39.1644305076923,42.16664576153846,45.168861015384614,48.17107626923077,51.17329152307693,54.17550677692308,57.17772203076923,60.179937284615384,63.18215253846154,66.1843677923077,69.18658304615386,{"y":72.1887983,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.16,33.53010060813846,33.90020121627692,34.270301824415384,34.64040243255384,35.010503040692306,35.38060364883077,35.75070425696923,36.120804865107694,36.49090547324616,36.861006081384616,37.23110668952308,37.60120729766154,{"y":37.9713079058,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.16,32.569107646153846,31.978215292307688,31.387322938461537,30.796430584615383,30.20553823076923,29.614645876923074,29.02375352307692,28.43286116923077,27.841968815384615,27.25107646153846,26.66018410769231,26.06929175384615,{"y":25.4783994,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.05,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.63,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.38,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.8,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.24,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":50.9,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.56,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":48.04,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":41.15,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":33.16,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€72.19

Average Price Target€37.97

Lowest Price Target€25.48

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Allen Lutz

Bank of America Securities

€27.18

Sell

-8.13%

Downside

Reiterated

12/19/25

Hims & Hers Health: Softening Online Metrics and Uncertain GLP-1 Trajectory Drive Underperform (Sell) View

Glen Santangelo

Barclays

€40.76

Buy

37.81%

Upside

Initiated

12/08/25

Hims & Hers initiated with an Overweight at BarclaysHims & Hers initiated with an Overweight at Barclays

Jailendra Singh

Truist Financial

Hold

―

Reiterated

12/08/25

Analysts Are Neutral on These Healthcare Stocks: Hims & Hers Health (HIMS), Cross Country Healthcare (CCRN)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

€25.48

Sell

-13.87%

Downside

Reiterated

11/18/25

Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)

Daniel Grosslight

Citi

€25.48

Sell

-13.87%

Downside

Reiterated

11/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), LifeMD (NASDAQ: LFMD) and Hims & Hers Health (NYSE: HIMS)

Craig Hettenbach

Morgan Stanley

€33.97

Hold

14.84%

Upside

Reiterated

11/12/25

Hims & Hers Health Faces Declining User Engagement and Growth Challenges Amid Industry Pressures

Ryan MacDonald

Needham

Hold

―

Reiterated

11/06/25

Cautious Outlook Amid Strategic Expansion: Hold Rating for Hims & Hers Health

Justin Patterson

KeyBanc

Hold

―

Reiterated

11/04/25

KeyBanc Keeps Their Hold Rating on Hims & Hers Health (HIMS)

Jonna Kim

TD Cowen

€40.76

Hold

37.81%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS), BioNTech SE (NASDAQ: BNTX) and Precision BioSciences (NASDAQ: DTIL)

David Larsen

BTIG

€72.19

Buy

144.04%

Upside

Reiterated

11/03/25

Strong Buy Rating for Hims & Hers Health: Impressive Growth and Strategic Expansion Drive Future Potential

Michael Cherny

Leerink Partners

Hold

―

Reiterated

10/16/25

Wall Street Analysts Are Neutral on Top Healthcare Picks

Maria Ripps

Canaccord Genuity

€57.75

Buy

95.23%

Upside

Reiterated

09/12/25

Hims & Hers Health (HIMS) Gets a Buy from Canaccord Genuity

George Hill

Deutsche Bank

€36.52→€40.76

Hold

37.81%

Upside

Reiterated

08/06/25

Hims & Hers price target raised to $48 from $43 at Deutsche BankHims & Hers price target raised to $48 from $43 at Deutsche Bank

Korinne Wolfmeyer

Piper Sandler

€29.72→€33.12

Hold

11.97%

Upside

Reiterated

05/06/25

Piper Sandler Remains a Hold on Hims & Hers Health (HIMS)

Aaron Kessler

Seaport Global

€46.71

Buy

57.91%

Upside

Reiterated

03/01/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Allen Lutz

Bank of America Securities

€27.18

Sell

-8.13%

Downside

Reiterated

12/19/25

Hims & Hers Health: Softening Online Metrics and Uncertain GLP-1 Trajectory Drive Underperform (Sell) View

Glen Santangelo

Barclays

€40.76

Buy

37.81%

Upside

Initiated

12/08/25

Hims & Hers initiated with an Overweight at BarclaysHims & Hers initiated with an Overweight at Barclays

Jailendra Singh

Truist Financial

Hold

―

Reiterated

12/08/25

Analysts Are Neutral on These Healthcare Stocks: Hims & Hers Health (HIMS), Cross Country Healthcare (CCRN)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

€25.48

Sell

-13.87%

Downside

Reiterated

11/18/25

Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)

Daniel Grosslight

Citi

€25.48

Sell

-13.87%

Downside

Reiterated

11/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), LifeMD (NASDAQ: LFMD) and Hims & Hers Health (NYSE: HIMS)

Craig Hettenbach

Morgan Stanley

€33.97

Hold

14.84%

Upside

Reiterated

11/12/25

Hims & Hers Health Faces Declining User Engagement and Growth Challenges Amid Industry Pressures

Ryan MacDonald

Needham

Hold

―

Reiterated

11/06/25

Cautious Outlook Amid Strategic Expansion: Hold Rating for Hims & Hers Health

Justin Patterson

KeyBanc

Hold

―

Reiterated

11/04/25

KeyBanc Keeps Their Hold Rating on Hims & Hers Health (HIMS)

Jonna Kim

TD Cowen

€40.76

Hold

37.81%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS), BioNTech SE (NASDAQ: BNTX) and Precision BioSciences (NASDAQ: DTIL)

David Larsen

BTIG

€72.19

Buy

144.04%

Upside

Reiterated

11/03/25

Strong Buy Rating for Hims & Hers Health: Impressive Growth and Strategic Expansion Drive Future Potential

Michael Cherny

Leerink Partners

Hold

―

Reiterated

10/16/25

Wall Street Analysts Are Neutral on Top Healthcare Picks

Maria Ripps

Canaccord Genuity

€57.75

Buy

95.23%

Upside

Reiterated

09/12/25

Hims & Hers Health (HIMS) Gets a Buy from Canaccord Genuity

George Hill

Deutsche Bank

€36.52→€40.76

Hold

37.81%

Upside

Reiterated

08/06/25

Hims & Hers price target raised to $48 from $43 at Deutsche BankHims & Hers price target raised to $48 from $43 at Deutsche Bank

Korinne Wolfmeyer

Piper Sandler

€29.72→€33.12

Hold

11.97%

Upside

Reiterated

05/06/25

Piper Sandler Remains a Hold on Hims & Hers Health (HIMS)

Aaron Kessler

Seaport Global

€46.71

Buy

57.91%

Upside

Reiterated

03/01/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

1 Month

xxx

Success Rate

15/25 ratings generated profit

Average Return

+1.87%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +1.87% per trade.

3 Months

xxx

Success Rate

18/25 ratings generated profit

Average Return

+2.34%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +2.34% per trade.

1 Year

Allen LutzBank of America Securities

Success Rate

21/25 ratings generated profit

Average Return

+30.02%

reiterated a sell rating 7 days ago

Copying Allen Lutz's trades and holding each position for 1 Year would result in 84.00% of your transactions generating a profit, with an average return of +30.02% per trade.

2 Years

xxx

Success Rate

21/25 ratings generated profit

Average Return

+36.14%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.00% of your transactions generating a profit, with an average return of +36.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

82W Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 82W has received 2 Buy Ratings, 17 Hold Ratings, and 15 Sell Ratings. 82W average Analyst price target in the past 3 months is 37.97.

Each month's total comprises the sum of three months' worth of ratings.

82W Financial Forecast

82W Earnings Forecast

Next quarter’s earnings estimate for 82W is €0.04 with a range of -€0.03 to €0.13. The previous quarter’s EPS was €0.05. 82W beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.

82W Sales Forecast

Next quarter’s sales forecast for 82W is €529.15M with a range of €519.73M to €547.00M. The previous quarter’s sales results were €511.82M. 82W beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.

82W Stock Forecast FAQ

What is DE:82W’s average 12-month price target, according to analysts?

Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 37.97.

What is DE:82W’s upside potential, based on the analysts’ average price target?

Hims & Hers Health has 28.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hims & Hers Health a Buy, Sell or Hold?

Hims & Hers Health has a consensus rating of Hold, which is based on 2 buy ratings, 6 hold ratings and 3 sell ratings.

What is Hims & Hers Health’s share price target?

The average share price target for Hims & Hers Health is 37.97. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €72.19 ,and the lowest forecast is €25.48. The average share price target represents 28.37% Increase from the current price of €29.58.

What do analysts say about Hims & Hers Health?

Hims & Hers Health’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Hims & Hers Health?

To buy shares of DE:82W, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Hims & Hers Health (82W) Stock Forecast & Price Target

82W Analyst Ratings

82W Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hims & Hers Health

82W Analyst Recommendation Trends

82W Financial Forecast

82W Earnings Forecast

82W Sales Forecast

82W Stock Forecast FAQ

Detailed List of Analyst Forecasts